In the context of vitamin D-mediated hypercalcemia, glucocorticoids may be used to decrease intestinal calcium absorption to correct serum calcium levels, while the induction of CYP24A1 may help to decrease active vitamin D metabolites’ half-lives (Figure 3). The gene discussed is CYP24A1; the disease is hypercalcemia disease.